Paul Bisaro - Zoetis Inc Independent Director


USD 174.21  2.32  1.35%   

Mr. Paul M. Bisaro is Independent Director of the Company. Mr. Bisaro was the Executive Chairman of the board of directors of Allergan plc from July 2014 to October 2016. Until June 2014, Mr. Bisaro formerly served as President and Chief Executive Officer from March 2017 to May 2018. Mr. Bisaro was the Executive Chairman of the board of directors of Allergan plc from July 2014 to October 2016. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis, a global pharmaceutical company . He was appointed President, Chief Executive Officer and a member of the board of Watson Pharmaceuticals in September 2007 and was later appointed Chairman of the board of Watson Pharmaceuticals in October 2013. Prior to joining Watson, Mr. Bisaro was President, Chief Operating Officer and a member of the board of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company, from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999 served in various additional capacities including Senior Vice President Strategic Business Development. Prior to joining Barr, Mr. Bisaro was associated with the law firm Winston Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. Mr. Bisaro currently serves on the Board of Visitors of The Catholic University of Americas Columbus School of Law. Mr. Bisaro previously served on the boards of Allergan plc from 2007 to 2018 and Zimmer Biomet Holdings, Inc., a world leader in musculoskeletal health solutions, from 2013 to 2017. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C. Mr. Bisaros business, management and leadership experience, his understanding of the pharmaceutical industry, and his public company board experience make him a valuable member of our Board.
Age: 59  Director Since 2015      
973 822-7000
Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C.

Zoetis Inc Management Efficiency

Zoetis Inc Cl has Return on Asset of 12.77 % which means that on every $100 spent on asset, it made $12.77 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 48.91 %, implying that it generated $48.91 on every 100 dollars invested. Zoetis Inc management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/02/2022, Return on Sales is likely to grow to 0.28, while Return on Investment is likely to drop 21.80. Zoetis Inc Current Assets are relatively stable at the moment as compared to the past year. Zoetis Inc reported last year Current Assets of 6.93 Billion. As of 07/02/2022, Tax Assets is likely to grow to about 159.3 M, while Assets Non Current are likely to drop slightly above 3.5 B.
The company has 6.79 B in debt with debt to equity (D/E) ratio of 1.49, which is OK given its current industry classification. Zoetis Inc Cl has a current ratio of 3.78, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Zoetis Inc until it has trouble settling it off, either with new capital or with free cash flow. So, Zoetis Inc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zoetis Inc Cl sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zoetis to invest in growth at high rates of return. When we think about Zoetis Inc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives


Christopher DavisCoca-Cola
William BrodyInternational Business Machines
Kathryn FullerAlcoa Corp
Ronald BlaylockPfizer Inc
Thomas MayBank Of America
Frances FergussonPfizer Inc
Dambisa MoyoChevron Corp
James OwensAlcoa Corp
Denise RamosBank Of America
Susan BiesBank Of America
David WeinbergCoca-Cola
Michael EskewInternational Business Machines
Amy AlvingAlcoa Corp
Robert YostBank Of America
Joseph HooleyExxon Mobil Corp
Herbert AllenCoca-Cola
Samuel PiazzaATT Inc
David FarrInternational Business Machines
Thomas BuberlInternational Business Machines
Maria LagomasinoCoca-Cola
Matthew RoseATT Inc
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis Inc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 12100 people. Zoetis Inc Cl (ZTS) is traded on New York Stock Exchange in USA and employs 12,100 people.

Zoetis Inc Cl Leadership Team

Elected by the shareholders, the Zoetis Inc's board of directors comprises two types of representatives: Zoetis Inc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zoetis. The board's role is to monitor Zoetis Inc's management team and ensure that shareholders' interests are well served. Zoetis Inc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zoetis Inc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
Wafaa Mamilli, Executive Vice President and Chief Information and Digital Officer
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations
Linda Rhodes, Independent Director
Timothy Bettington, Executive Vice President and President U.S. Operations
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sherry Pudloski, Executive Vice President - Corporate Affairs and Communications
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Antoinette Leatherberry, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Wetteny Joseph, Chief Financial Officer, Executive Vice President, Head of Business Development
Sandra Beaty, Executive Vice President - Corporate Affairs
Robert Kelly, Executive Vice President and President International Operations
J McFarland, Executive Vice President and Chief Medical Officer
Robert Polzer, Executive Vice President and Presidentident of Research and Development
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Abhay Nayak, Executive Vice President Head of Strategy and Accelerated Growth Businesses
Juan Alaix, Chief Executive Officer, Director

Zoetis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zoetis Inc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Zoetis Inc Investors Sentiment

The influence of Zoetis Inc's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Zoetis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Zoetis Inc Implied Volatility

Zoetis Inc's implied volatility exposes the market's sentiment of Zoetis Inc Cl stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Zoetis Inc's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Zoetis Inc stock will not fluctuate a lot when Zoetis Inc's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zoetis Inc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zoetis Inc's short interest history, or implied volatility extrapolated from Zoetis Inc options trading.

Current Sentiment - ZTS

Zoetis Inc Cl Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis Inc Cl. What is your take regarding investing in Zoetis Inc Cl? Are you bullish or bearish?
98% Bullish
2% Bearish

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Your Current Watchlist. Note that the Zoetis Inc Cl information on this page should be used as a complementary analysis to other Zoetis Inc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Zoetis Stock analysis

When running Zoetis Inc Cl price analysis, check to measure Zoetis Inc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis Inc is operating at the current time. Most of Zoetis Inc's value examination focuses on studying past and present price action to predict the probability of Zoetis Inc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Zoetis Inc's price. Additionally, you may evaluate how the addition of Zoetis Inc to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Transaction History
View history of all your transactions and understand their impact on performance
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Is Zoetis Inc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zoetis Inc. If investors know Zoetis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zoetis Inc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
82 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Zoetis Inc Cl is measured differently than its book value, which is the value of Zoetis that is recorded on the company's balance sheet. Investors also form their own opinion of Zoetis Inc's value that differs from its market value or its book value, called intrinsic value, which is Zoetis Inc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zoetis Inc's market value can be influenced by many factors that don't directly affect Zoetis Inc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zoetis Inc's value and its price as these two are different measures arrived at by different means. Investors typically determine Zoetis Inc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zoetis Inc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.